CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously

CymaBay Therapeutics Inc. is taking a similar route to market with its PPAR delta agonist seladelpar as Intercept Pharmaceuticals Inc. took with obeticholic acid (OCA) – and with a drug that is the same class as Genfit SA, another market leader. CymaBay hopes to obtain approval first in primary biliary cholangitis (PBC), as Intercept did, and then move on to non-alcoholic steatohepatitis (NASH).

Seladelpar is a selective agonist of peroxisome proliferator-activated receptor delta (PPAR delta), while Genfit’s elafibranor, in Phase III in NASH...